- Home
- NEGG vs GNLX Comparison
NEGG vs GNLX Comparison
Compare NEGG & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- GNLX
- Stock Information
- Founded
- NEGG 2001
- GNLX 2001
- Country
- NEGG United States
- GNLX United States
- Employees
- NEGG N/A
- GNLX N/A
- Industry
- NEGG Other Specialty Stores
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- GNLX Health Care
- Exchange
- NEGG Nasdaq
- GNLX Nasdaq
- Market Cap
- NEGG 122.3M
- GNLX 112.5M
- IPO Year
- NEGG 2010
- GNLX 2023
- Fundamental
- Price
- NEGG $49.24
- GNLX $3.44
- Analyst Decision
- NEGG
- GNLX Strong Buy
- Analyst Count
- NEGG 0
- GNLX 4
- Target Price
- NEGG N/A
- GNLX $17.75
- AVG Volume (30 Days)
- NEGG 646.8K
- GNLX 152.2K
- Earning Date
- NEGG 08-28-2025
- GNLX 08-13-2025
- Dividend Yield
- NEGG N/A
- GNLX N/A
- EPS Growth
- NEGG N/A
- GNLX N/A
- EPS
- NEGG N/A
- GNLX N/A
- Revenue
- NEGG $1,235,576,000.00
- GNLX N/A
- Revenue This Year
- NEGG N/A
- GNLX N/A
- Revenue Next Year
- NEGG N/A
- GNLX N/A
- P/E Ratio
- NEGG N/A
- GNLX N/A
- Revenue Growth
- NEGG N/A
- GNLX N/A
- 52 Week Low
- NEGG $3.32
- GNLX $1.60
- 52 Week High
- NEGG $56.00
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- NEGG 91.69
- GNLX 65.71
- Support Level
- NEGG $15.31
- GNLX $2.80
- Resistance Level
- NEGG $17.52
- GNLX $3.61
- Average True Range (ATR)
- NEGG 4.56
- GNLX 0.22
- MACD
- NEGG 2.70
- GNLX 0.05
- Stochastic Oscillator
- NEGG 85.35
- GNLX 80.23
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.